Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

verfasst von: Jing Wang, Renbing Jia, Yidan Zhang, Xiaofang Xu, Xin Song, Yixiong Zhou, He Zhang, Shengfang Ge, Xianqun Fan

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Gemcitabine (GEM), a new cytotoxic agent, was shown to be effective against uveal melanoma (UM) which is noted for its resistance to chemotherapy. In this study, we found the different sensitivities to GEM in UM cell lines and identified apoptotic cell death as the cause of GEM cytotoxicity. Both UM cell lines showed an increase in Bax protein levels and activation of cleaved Caspase 3. Additionally, SP6.5 cells showed a gradual increase in Bcl-2 expression over time, whereas VUP cells showed almost none. After interfering in the expression of Bcl-2, the sensitivity to GEM was obviously enhanced in SP6.5 cells. These results suggest that an increase in Bax plays a crucial role in apoptotic cell death induced by GEM in the absence of p53. Moreover, inhibition of Bcl-2 expression can efficiently enhance the cytotoxic effect of, and sensitivity to, GEM in UM cells.
Literatur
1.
2.
Zurück zum Zitat Zoli W. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004;10(4):1500–7.PubMedCrossRef Zoli W. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004;10(4):1500–7.PubMedCrossRef
3.
Zurück zum Zitat Ramanathan RK. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin Oncol. 1997;24:440–54.PubMed Ramanathan RK. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin Oncol. 1997;24:440–54.PubMed
4.
Zurück zum Zitat Yamagishi Y. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146–54.PubMedCrossRef Yamagishi Y. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146–54.PubMedCrossRef
5.
Zurück zum Zitat Neale MH. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487–93.PubMedCentralPubMedCrossRef Neale MH. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487–93.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Schmittel A. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17(12):1826–9.PubMedCrossRef Schmittel A. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17(12):1826–9.PubMedCrossRef
7.
Zurück zum Zitat Atzpodien J. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol. 2008;62(4):685–8.PubMedCrossRef Atzpodien J. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol. 2008;62(4):685–8.PubMedCrossRef
8.
Zurück zum Zitat Ruiz van Haperen VW. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46:762–6.PubMedCrossRef Ruiz van Haperen VW. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46:762–6.PubMedCrossRef
9.
Zurück zum Zitat Plunkett W. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.PubMed Plunkett W. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.PubMed
10.
Zurück zum Zitat Chen M. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000;45(5):369–74.PubMedCrossRef Chen M. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000;45(5):369–74.PubMedCrossRef
11.
Zurück zum Zitat Galmarini CM. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002;97(4):439–45.PubMedCrossRef Galmarini CM. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002;97(4):439–45.PubMedCrossRef
12.
Zurück zum Zitat Zhou Y. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res. 2010;23(5):661–74.PubMedCrossRef Zhou Y. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res. 2010;23(5):661–74.PubMedCrossRef
13.
Zurück zum Zitat Cun B. Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA. Tumour Biol. 2013;34(3):1801–6.PubMedCrossRef Cun B. Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA. Tumour Biol. 2013;34(3):1801–6.PubMedCrossRef
14.
Zurück zum Zitat Zhang Y. Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells. Int J Mol Sci. 2013;14(4):15092–104.PubMedCentralPubMedCrossRef Zhang Y. Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells. Int J Mol Sci. 2013;14(4):15092–104.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Zhang H. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther. 2009;17(1):57–64.PubMedCrossRef Zhang H. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther. 2009;17(1):57–64.PubMedCrossRef
16.
Zurück zum Zitat Wang J. Differential expression of Mart-1 in human uveal melanoma cells. Mol Med Rep. 2011;4(5):799–803.PubMed Wang J. Differential expression of Mart-1 in human uveal melanoma cells. Mol Med Rep. 2011;4(5):799–803.PubMed
17.
Zurück zum Zitat Xu X. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011;38(5):1385–93.PubMed Xu X. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011;38(5):1385–93.PubMed
19.
Zurück zum Zitat Kastan MB. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15.PubMedCrossRef Kastan MB. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15.PubMedCrossRef
21.
Zurück zum Zitat Huang X. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br J Ophthalmol. 2012;96:1331–8.PubMedCrossRef Huang X. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br J Ophthalmol. 2012;96:1331–8.PubMedCrossRef
22.
Zurück zum Zitat Brady HJ. T cells from bax α transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J. 1996;15(6):1221–30.PubMed Brady HJ. T cells from bax α transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J. 1996;15(6):1221–30.PubMed
23.
Zurück zum Zitat Oltvai Z. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–19.PubMedCrossRef Oltvai Z. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–19.PubMedCrossRef
24.
Zurück zum Zitat Zhang J. Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3′-UTR microRNA. Int J Cancer. 2010;126(9):2229–39.PubMedCentralPubMed Zhang J. Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3′-UTR microRNA. Int J Cancer. 2010;126(9):2229–39.PubMedCentralPubMed
25.
Zurück zum Zitat Chang GC. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004;502(3):169–83.PubMedCrossRef Chang GC. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004;502(3):169–83.PubMedCrossRef
26.
Zurück zum Zitat Yao Y. Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells. Oncol Lett. 2012;4(1):163–7.PubMedCentralPubMed Yao Y. Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells. Oncol Lett. 2012;4(1):163–7.PubMedCentralPubMed
27.
Metadaten
Titel
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells
verfasst von
Jing Wang
Renbing Jia
Yidan Zhang
Xiaofang Xu
Xin Song
Yixiong Zhou
He Zhang
Shengfang Ge
Xianqun Fan
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1156-6

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.